Where is RevaTis located?

RevaTis is headquartered in Luxemburg, United States.

How many employees does RevaTis have?

As of Aug 31, 2026, the latest employee count at RevaTis is 14.

Where does RevaTis rank among its competitors?

RevaTis ranks 675th amongst 2120 active competitors, of which 488 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was LifeMine Therapeutics, which secured $75M in Aug, 2026.

Who are the top competitors of RevaTis?

RevaTis' top competitors include Antheia, Transcenta and Pandorum. Among them, LifeMine Therapeutics secured the most recent funding round in August, 2026.

RevaTis - 2026 Company Profile, Team, Funding & Competitors

Company Details

Revatis is a provider of the undifferentiated muscle-derived stem. The company has patented technology to obtain pluripotent adult Mesenchymal Stem Cells from a minimally invasive muscle micro-biopsy. It is a spin-off from Liege University, in Belgium, and developing regenerative medicine and cell therapy.

Website: revatis.com/en
Email ID: *****@revatis.com
Phone Number: +32 **********

Key Metrics

Founded Year

2013

Location

Luxemburg, United States

Stage

Funding Raised

Investors

Noshaq & 1 more

Ranked

675^th among 2120 active competitors

Employee Count

14 as on Aug 31, 2026

Similar Companies

Antheia & 2863 more

View RevaTis' full profile

RevaTis is a funded company. RevaTis has 2 institutional investors.

View details of RevaTis's funding rounds and investors

RevaTis' employee count trend

RevaTis has 14 employees as of Aug 26. Here is RevaTis's employee count trend over the years:

Uncover RevaTis' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of RevaTis include Antheia, Transcenta and Pandorum. Here is the list of Top 10 competitors of RevaTis, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	67/100
2nd	Transcenta 2019, Suzhou (China), Public	Developer of antibody-based therapeutics	$205M	Lilly Asia Ventures, Temasek & 11 others	66/100
3rd	Pandorum 2011, Bengaluru (India), Series B	Developer of regenerative medicine and 3D tissues	$52.1M	Indian Angel Network, BTB Venture & 89 others	65/100
4th	Akeso 2012, Zhongshan (China), Public	Developer of antibody drug conjugates for the treatment of broad spectrum diseases	$195M	Loayal Valley Capital, Sino Biopharmaceutical ... & 18 others	65/100
5th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Cormorant Asset Management, Atlas Venture ... & 14 others	64/100
6th	Novogene Corporation 2011, Beijing (China), Series B	Provider of genomic services and solutions	$75M	SDIC Innovation, CMB International Capital ... & 4 others	64/100
7th	Fermentalg 2005, Libourne (France), Public	Innovating with algae for sustainable solutions in nutrition and environmental impact	$30.3M	Demeter, Smalt Capital & 14 others	63/100
8th	Microban 1994, Huntersville (United States), Acquired	Antimicrobial and odor control technologies for durable product protection and freshness	$64.6M	TA Associates, UBS & 1 others	63/100
9th	LifeMine Therapeutics 2016, Watertown (United States), Series E	Developer of novel drugs from fungi via genome mining and recombinant overexpression	$563M	Fidelity Investments, 6 Dimensions Capital ... & 17 others	63/100
10th	One Biosciences 2020, Paris (France), Series A	Developer of single-cell therapeutics solutions to treat multiple health disorders	$22.4M	BLAST Premier, Redmile Group & 6 others	62/100
675th	RevaTis 2013, Luxemburg (United States), Funding Raised	Provider of undifferentiated muscle-derived stem	-	Noshaq, WBC Ventures	31/100